A Phase 1 interventional study of TAK-951 and TAK-951 Placebo in Healthy Volunteer, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults.
The main aims of this study are as follows:
Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours.
Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.
The drug being tested in this study is called TAK-951. The study will evaluate the safety, tolerability and PK of TAK-951 in healthy participants.
The study will enroll approximately 40 healthy participants. Each cohort will have 8 participants to be randomized and a minimum of 3 cohorts will be evaluated. Participants will be randomly assigned (by chance, like flipping a coin) to receive TAK-951 or placebo in a 6:2 ratio in one of the following 3 cohorts, which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
Sentinel dosing will be done in first 2 participants in each cohort. The dosing in rest of the cohort will done if there are no significant safety or tolerability concerns. Additional 2 cohorts, each cohort with 8 participants may be added in study to evaluate additional intravenous dosing regimen after clinical data analysis of first 3 cohorts. Dosing of the subsequent cohort will be based on the analysis of the previous cohort's data.
This single-center trial will be conducted in the United States. The overall time to participate in this study is up to 57 days. All participants will return to clinic after 14 and 28 days after the last visit to the clinic for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-951 20 microgram (mcg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1.
Drug: TAK-951 · Drug: TAK-951 Placebo
TAK-951 1 milligram (mg) or TAK-951 placebo-matching, infusion, intravenously, over a period of 60 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
Drug: TAK-951 · Drug: TAK-951 Placebo
TAK-951 1 mg or TAK-951 placebo-matching, infusion, intravenously, over a period of 120 minutes on Day 1. Dose level will be determined based on safety, tolerability and PK data from previous cohorts.
Drug: TAK-951 · Drug: TAK-951 Placebo
TAK-951 intravenous infusion.
TAK-951 placebo-matching intravenous infusion.
Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline up to Day 29
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values
Time frame: Baseline up to Day 2
Number of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values
Time frame: Baseline up to Day 2
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
Time frame: Baseline up to Day 2
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Values
Time frame: Baseline up to Day 29
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Ceoi: Plasma Concentration at the End of Infusion for TAK-951
Time frame: Day 1: at the end of infusion (at 30 hours post-infusion)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
T1/2z: Terminal Disposition Phase Half-life for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
λz: Terminal Disposition Phase Rate Constant for TAK-951
Time frame: Day 1 pre-dose and at multiple time points (up to 30 hours) post-dose
Number of Participants With Positive Anti-drug Antibodies (ADA) in Serum
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
Time frame: Baseline up to Day 29
Participants took part in the study at 1 investigative site in the United States from 07 July 2020 to 27 May 2021.
| Milestone | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Started | 4 | 2 | 2 | 6 | 6 | 6 | 6 |
| Completed | 4 | 2 | 2 | 6 | 6 | 5 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Reported One or More Treatment-emergent Adverse Events (TEAEs) | 1 | 0 | 1 | 3 | 1 | 3 | 1 |
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12- Lead Electrocardiogram (ECG) Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| nanogram*hour per milliliter (ng*hr/mL) | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951 | 2.758 ± 25.1 | 110.4 ± 11.0 | 127.7 ± 23.9 | 133.2 ± 9.5 |
| nanogram per milliliter (ng/mL) | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|
| Ceoi: Plasma Concentration at the End of Infusion for TAK-951 | 0.5203 ± 143.2 | 48.95 ± 15.9 | 37.03 ± 38.4 | 27.06 ± 9.1 |
| ng*hr/mL | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-951 | 2.722 ± 25.4 | 110.0 ± 10.8 | 127.2 ± 24.0 | 132.5 ± 9.5 |
| hour | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|
| T1/2z: Terminal Disposition Phase Half-life for TAK-951 | 4.025 ± 0.7100 | 4.670 ± 0.5576 | 4.454 ± 0.5124 | 4.640 ± 0.3410 |
| per hour (1/hour) | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|
| λz: Terminal Disposition Phase Rate Constant for TAK-951 | 0.1781 ± 0.040265 | 0.1501 ± 0.016879 | 0.1574 ± 0.018543 | 0.1500 ± 0.010488 |
ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.
| Participants | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Positive Anti-drug Antibodies (ADA) in Serum | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over TEAEs were adverse events that started after the first dose of study drug (Baseline) up to Day 29. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohorts 1 to 2, Treatment P1: Placebo Pooled | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Cohort 3, Treatment P2: Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cohort 4, Treatment P3: Placebo | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 1, Treatment A: TAK-951 20 mcg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 2, Treatment B: TAK-951 1.0 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cohort 3, Treatment C: TAK-951 1.0 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Cohort 4, Treatment D: TAK-951 1.0 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg |
|---|---|---|---|---|---|---|---|
| Medical device site reactionGeneral disorders | 0/4 | 0/2 | 1/2 | 0/6 | 0/6 | 0/6 | 0/6 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/4 | 0/2 | 0/2 | 0/6 | 0/6 | 0/6 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 0/2 | 0/2 | 0/6 | 0/6 | 1/6 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/2 | 0/2 | 0/6 | 0/6 | 0/6 | 1/6 |
| DizzinessNervous system disorders | 0/4 | 0/2 | 0/2 | 1/6 | 1/6 | 1/6 | 0/6 |
| Heart rate increasedInvestigations | 0/4 | 0/2 | 0/2 | 0/6 | 1/6 | 0/6 | 0/6 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/4 | 0/2 | 0/2 | 0/6 | 0/6 | 1/6 | 0/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/4 | 0/2 | 0/2 | 1/6 | 0/6 | 0/6 | 0/6 |
| Orthostatic heart rate response increasedInvestigations | 0/4 | 0/2 | 0/2 | 0/6 | 0/6 | 1/6 | 0/6 |
| PalpitationsCardiac disorders | 0/4 | 0/2 | 0/2 | 1/6 | 0/6 | 0/6 | 0/6 |
The safety analysis set consisted of all participants who were enrolled and received the full or partial dose of study drug or placebo.
| Age, Categorical(Participants) | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 2 | 6 | 6 | 6 | 6 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
| Male | 4 | 2 | 2 | 4 | 6 | 5 | 6 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 4 | 2 | 2 | 6 | 6 | 5 | 4 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 5 |
| White | 3 | 1 | 2 | 4 | 5 | 4 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohorts 1 to 2, Treatment P1: Placebo Pooled | Cohort 3, Treatment P2: Placebo | Cohort 4, Treatment P3: Placebo | Cohort 1, Treatment A: TAK-951 20 mcg | Cohort 2, Treatment B: TAK-951 1.0 mg | Cohort 3, Treatment C: TAK-951 1.0 mg | Cohort 4, Treatment D: TAK-951 1.0 mg | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 4 | 2 | 2 | 6 | 6 | 6 | 6 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2020 to primary completion in May 2021, 10 months.
Results were first posted in Mar 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-951